|  |  |
| --- | --- |
| **Agenda Item No:** | **18b** |



|  |  |
| --- | --- |
| **Report to:** | Humber & North Yorkshire Integrated Care Board |
| **Date of Meeting:** | 13 November 2024 |
| **Subject:** | **Question to the Board** |
| **Director Sponsor:** | Karina Ellis, Executive Director of Corporate Affairs |
| **Author:** | Mike Napier, Director of Governance and Board Secretary  Governance & Development Team |

|  |
| --- |
| **STATUS OF THE REPORT:**  Approve  Discuss  Assurance  Information  A Regulatory Requirement |

|  |
| --- |
| **SUMMARY OF REPORT:**  In accordance with ICB procedures, there is a standing item on the agenda of board meetings held in public where members of the public can submit up to two questions in advance relating to any item on the published agenda. It is at the discretion of the ICB Chair whether other questions not relating to an agenda item are taken at the meeting.  A public question received on the 7 October 2024, which has acknowledged by the enquirer, was too late for consideration to be given at the Board meeting on the 9October 2024 and therefore, received and approved for consideration by the Chair at the November meeting as follows: -  While the ICB Board published its papers, agendas and minutes, webcasts its meetings (with catch-up) and invites public written questions, the same does not appear to be the case for Executive and Partnership meetings of its Collaboratives or Places.  This is in marked contrast to equivalent meetings of Local Authorities, for example Executive Committees, Health & Wellbeing Boards and Scrutiny Committees, where in many cases verbal questions are provided for as well.   1. Does the HNY ICB Board embrace the ten principles set out in the July 2022 Statutory Guidance “Working in Partnership with People and Communities” (Chapter 4, pp 24-31)? 2. Does the Board consider holding only closed meetings of the different leadership meetings of its Collaboratives and Places to be consistent with principles of openness and transparency contained within such ten principles? 3. Will the ICB Board consider the rapid introduction (with deadlines) of public access to such Collaborative and Place meetings (including public questions), subject to the usual precisely defined exceptions where business or papers will be considered only in private session.   **Notes**  The matter becomes of greater importance where statutory responsibilities of the ICB Board are delegated to such Places or Collaboratives.  The provisions of the Health Overview and Scrutiny Committee Principles (DHSC Guidance, published 29 July 2022) may also be relevant.  The section headed “The benefits of scrutiny” begins:  ***“****Proactive and constructive scrutiny of health, care and public health services, done effectively, can build constructive relationships that deliver better outcomes for local people and communities; the people who represent them, and the commissioners and providers of health and care services.”*  The matter might also be considered in the context of the ICB’s proposed Working with People and Communities Strategy*: “It is vital that we actively listen and openly share.”*  **RECOMMENDATIONS:**  Members are asked to:   1. Receive the question and note that the response provided to the meeting will subsequently be sent in writing to the enquirer. |

|  |
| --- |
| **ICB STRATEGIC OBJECTIVE** |

|  |  |
| --- | --- |
| Leading for Excellence |  |
| Leading for Prevention |  |
| Leading for Sustainability |  |
| Voice at the Heart |  |

|  |
| --- |
| **IMPLICATIONS** |

|  |  |
| --- | --- |
| Finance | No adverse implications identified in relation to the submission of the question. |
| Quality | No adverse implications identified in relation to the submission of the question. |
| HR | No adverse implications identified in relation to the submission of the question. |
| Legal / Regulatory | No adverse implications identified in relation to the submission of the question. |
| Data Protection / IG | No adverse implications identified in relation to the submission of the question. |
| Health inequality / equality | No adverse implications identified in relation to the submission of the question. |
| Conflict of Interest Aspects | No adverse implications identified in relation to the submission of the question. |
| Sustainability | No adverse implications identified in relation to the submission of the question. |

|  |
| --- |
| **ASSESSED RISK:**  There are no risks identified in relation to this paper. |

|  |
| --- |
| **MONITORING AND ASSURANCE:**  Monitoring and assurance of the matter will be undertaken by the ICB Board. |

|  |
| --- |
| **ENGAGEMENT:**  In line with the ICB procedure, the Board Secretary will facilitate subsequent follow-up, as required. |

|  |
| --- |
| **REPORT EXEMPT FROM PUBLIC DISCLOSURE** No  Yes |